Topics

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

2019-10-11 10:03:46 | BioPortfolio

Summary

The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia coli (ExPEC). E. coli bacteria are a leading cause of serious infections. Especially adults older than 60 years have a higher risk of developing such infections. To date, there is no vaccine available to prevent E. coli infections. To support the development of a vaccine, more information about E. coli infections is first needed. This information will be collected in the current study, such as:

- Medical information such as medical history, diagnosis, duration of hospitalization

- Treatment and outcome of the Extraintestinal pathogenic Escherichia coli (ExPEC)

- Laboratory information

Description

Janssen Research & Development is developing ExPEC10V, a 10-valent conjugate vaccine comprising the 10 most predominant O-polysaccharides of ExPEC.

Invasive ExPEC Disease (IED) is defined as an acute illness consistent with bacterial infection that is microbiologically confirmed either by the isolation and identification of E. coli from blood or other normally sterile body sites, or by the isolation and identification of E. coli from urine in a patient with signs and symptoms of invasive disease (presence of systemic inflammatory response syndrome [SIRS], sepsis or septic shock) and no other identifiable source of infection.

ExPEC is the most common cause of infection in humans resulting from gram-negative bacteria. ExPEC comprises a pathogenic group of E. coli strains, possessing the ability to colonize and infect normally sterile body sites and to cause Invasive ExPEC Disease (IED).

ExPEC causes the vast majority of urinary tract infections (UTIs), is the second most frequent cause of neonatal bacteremia and meningitis, and is a leading cause of adult IED, in particular bacteremia and sepsis.

Although IED affects all age categories, adults aged 60 years or older have an increased risk of developing IED, including bacteremia and sepsis. The incidence of community-acquired ExPEC bacteremia increases with age, occurring at a rate of 150/100,000 person-years in the United States (US) adults aged 65 years and older, and 452/100,000 person-years in adults aged 85 years and older. Similar trends have been observed in Europe. In the US, it is estimated that up to 40,000 patients die annually due to IED, in particular from E. coli sepsis. Overall case-fatality rates for ExPEC bacteremia range from 13% to 19% but may be much higher (up to 60%) in the elderly with healthcare-associated infections.

The increase in multidrug resistance (ie, resistance to two or more antibiotic classes) among ExPEC strains, such as E. coli sequence type 131:O25B, represents a major challenge for prevention and management of ExPEC infections. Global morbidity, hospitalization and mortality rates due to ExPEC infections are substantial and increasing due to aging populations and increasing prevalence of antibiotic resistant ExPEC strains, and associated with increasing healthcare costs in both Europe and the US.

This hospital-based prospective epidemiological study will assess the O-serotype and O-genotype distribution in E. coli isolates causing IED overall and by subgroup based on risk factors. Detailed demographic and clinical data, including information on hospital routes, from patients with IED will be collected in this study to further characterize the clinical setting in this patient population. This study will also provide data to compare the clinical criteria of IED used by the study site with the proposed Phase 3 clinical case definition for IED in adults aged 60 years or older for future clinical studies in this patient population. No study drug will be administered in this non interventional study.

Study Design

Conditions

E. Coli Infection

Status

Not yet recruiting

Source

UMC Utrecht

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-11T10:03:46-0400

Clinical Trials [506 Associated Clinical Trials listed on BioPortfolio]

The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection

The existing diarrhoeagenic Escherichia coli (E. coli) challenge model is already suitable for dietary interventions in its current form, targeted to impact on the immediate clinical sympt...

Antibiotic Resistant Community-Acquired E. Coli

The purpose of this study is to review patients with E. coli infections at UPMC from January 1, 2004 to December 31, 2005 to determine if these infections have arisen in the community rath...

Study to Collect Information About Serious Infections Caused by E.Coli Bacteria

The purpose of this study is to collect information from study participants who develop a serious infection caused by a bacterium called E.coli during a period of 12 months. This informati...

Clinical Experiment of Helicobacter Pylori Transmission

The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli. The study will also evaluate th...

Epidemiology of ST131 in Besançon University Hospital

The sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli that produce exten...

PubMed Articles [7704 Associated PubMed Articles listed on BioPortfolio]

A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa.

There are few studies describing Escherichia coli (E. coli) bloodstream infection (BSI) among children in Africa, yet E.coli is increasing in importance as a cause of antibiotic resistant infection in...

The role of the miR1976/CD105/integrin αvβ6 axis in vaginitis induced by Escherichia coli infection in mice.

Vaginitis is very common among women, especially women of childbearing age, and is associated with significantly increased risk of preterm birth and pelvic inflammatory diseases. An imbalance in the v...

Analysis of drug resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae in children with urinary tract infection.

To investigate the drug resistance of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli ) and Klebsiella pneumoniae (K. pneumoniae) in children with urinary tract infection ...

Low-dose inoculation of Escherichia coli achieves robust vaginal colonization and results in ascending infection accompanied by severe uterine inflammation in mice.

Escherichia coli infection of the female reproductive tract is a significant cause of disease in humans and animals, but simple animal models are lacking. Here we report that vaginal inoculation of ur...

NDM-1-producing Escherichia coli isolated from pigs induces persistent infection with limited pathogenicity.

NDM-1-producing Enterobacteriaceae are multidrug-resistant bacteria, also called superbacteria, that have become important global human health threats in recent years. However, data about NDM-1-produc...

Medical and Biotech [MESH] Definitions

Strains of Escherichia coli that possess virulence traits which allow them to invade, colonize, and induce disease in tissues outside of the GASTROINTESTINAL TRACT. They are a cause of URINARY TRACT INFECTIONS (UROPATHOGENIC ESCHERICHIA COLI); neonatal MENINGITIS; SEPSIS; PNEUMONIA; and SURGICAL WOUND INFECTION.

Strains of ESCHERICHIA COLI that are a subgroup of SHIGA-TOXIGENIC ESCHERICHIA COLI. They cause non-bloody and bloody DIARRHEA; HEMOLYTIC UREMIC SYNDROME; and hemorrhagic COLITIS. An important member of this subgroup is ESCHERICHIA COLI O157-H7.

An enterohemorrhagic Escherichia coli of the O subfamily that can cause severe FOODBORNE DISEASE. The H4 serotype strain produces SHIGA TOXINS and has been linked to human disease outbreaks, including some cases of HEMOLYTIC-UREMIC SYNDROME, resulting from contamination of foods by feces containing E. coli O104.

A verocytotoxin-producing serogroup belonging to the O subfamily of Escherichia coli which has been shown to cause severe food-borne disease. A strain from this serogroup, serotype H7, which produces SHIGA TOXINS, has been linked to human disease outbreaks resulting from contamination of foods by E. coli O157 from bovine origin.

A species of gram-negative, rod-shaped bacteria belonging to the K serogroup of ESCHERICHIA COLI. It lives as a harmless inhabitant of the human LARGE INTESTINE and is widely used in medical and GENETIC RESEARCH.

More From BioPortfolio on "Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)"

Quick Search

Relevant Topic

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...


Searches Linking to this Trial